Additional Doses & Boosters

Current Recommendations 

Boosters

Following approval from the Food and Drug Administration (FDA) [external link] and the Center for Disease Control and Prevention (CDC) [external link], authorized the Moderna and Pfizer-BioNTech COVID-19 bivalent mRNA vaccine as a primary series and second booster for those eligible. 

  • Use the CDC’s COVID-19 Booster Tool [external link] to determine your eligibility for your next COVID-19 vaccine.
  • People ages 6 months and older are recommended to receive the bivalent omicron dose at least 2 months after completion of the monovalent primary series or since their last monovalent booster dose.
  • People ages 12 and older who received Novavax COVID-19 vaccine as their primary series may receive the bivalent omicron dose at least 2 months after their last dose of COVID-19 vaccine. 

PFIZER

  • Individuals with no previous history of a bivalent mRNA COVID-19 booster: One bivalent COVID-19 booster at least 8 weeks after last monovalent dose 
  • Individuals 65 years and older: One additional bivalent dose may be administered at least 4 months after the previous bivalent dose 

MODERNA

  • Individuals with no previous history of a bivalent mRNA COVID-19 booster: One bivalent COVID-19 booster at least 8 weeks after last monovalent dose 
  • Individuals 65 years and older: One additional bivalent dose may be administered at least 4 months after the previous bivalent dose 

In addition, the CDC recommendations allow for “mixing and matching [external link],” and "Interchangeability of COVID vaccines" [external link] meaning individuals have a choice to receive a different vaccine as a booster than what they originally received.

Additional Doses

  • Information about the COVID-19 vaccination schedule for people who are moderately or severely immunocompromised will be available from the CDC [external link] soon.   

In addition, the CDC recommendations allow for “mixing and matching [external link],” meaning individuals have a choice to receive a different vaccine as a booster than what they originally received. 

People who are considered to be moderately to severely immunocompromised may include:

  • Those who have been receiving active cancer treatment for tumors or cancers of the blood.
  • Have received an organ transplant and are taking medicine to suppress the immune system.
  • Have received a stem cell transplant within the last two years or are taking medicine to suppress the immune system.
  • Are moderate or severe primary immunodeficiency (such as DiGeorge syndrome, Wiskott-Aldrich syndrome).
  • Have advanced or untreated HIV.
  • Are undergoing active treatment with high-dose corticosteroids or other drugs that may suppress your immune response.

For more information, see CDC's webpage on COVID-19 Vaccines for Moderately to Severely Immunocompromised People [external link].  

Questions?

Community members can call JCPH's COVID Vax Information Center (C-VIC) at 303-239-7000 and press option 1 for vaccine information.